Form 4: Alignment Healthcare CEO Sells Shares

Alignment Healthcare CEO John E. Kao has reported the sale of company stock totaling over 300,000 shares across multiple transactions in April 2026, executed under a Rule 10b5-1 trading plan.

Summary

• John E. Kao, CEO of Alignment Healthcare, Inc. (ALHC), reported transactions involving the sale of common stock on April 10, 2026, and April 13, 2026.
• The sales on April 10, 2026, involved 201,900 shares at a weighted-average price of $20.5807 and 13,801 shares at a weighted-average price of $21.3785.
• An additional sale of 82,299 shares occurred on April 13, 2026, at a weighted-average price of $20.798.
• These transactions were made pursuant to a Rule 10b5-1 trading plan adopted on November 21, 2025.
• Following these sales, Mr. Kao beneficially owns 1,784,868 shares of common stock, with a portion held indirectly through the JEK Trust.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant volume of shares sold by the CEO, despite being executed under a 10b5-1 plan.

Negatives

• CEO John E. Kao sold a significant number of shares (over 300,000) in April 2026.
• The sales occurred at prices ranging from $20.26 to $21.49 per share.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that insider selling, especially by a CEO, can sometimes be interpreted by the market as a signal of reduced confidence or a belief that the stock may be overvalued. However, the execution of these sales under a pre-arranged Rule 10b5-1 plan mitigates concerns about opportunistic trading based on non-public information.

Stakeholder Impact

• Shareholders may view the CEO's sale of a substantial number of shares with caution, potentially impacting short-term investor sentiment.
• The execution of sales under a Rule 10b5-1 plan indicates adherence to established governance procedures for insider transactions.

Key Dates

Recommendation

The filing reports insider selling by the CEO, which can be a negative signal. However, the sales were conducted under a pre-established Rule 10b5-1 plan, suggesting a planned diversification rather than a reaction to adverse non-public information. Without further financial performance data or strategic updates, a 'hold' recommendation is prudent, allowing investors to monitor future company performance and insider activity.

Keywords

Alignment Healthcare, ALHC, Form 4, Insider Trading, Stock Sale, CEO, Rule 10b5-1, Beneficial Ownership